CN110669137B - 一种多特异性抗体及其制备方法和用途 - Google Patents

一种多特异性抗体及其制备方法和用途 Download PDF

Info

Publication number
CN110669137B
CN110669137B CN201911015236.1A CN201911015236A CN110669137B CN 110669137 B CN110669137 B CN 110669137B CN 201911015236 A CN201911015236 A CN 201911015236A CN 110669137 B CN110669137 B CN 110669137B
Authority
CN
China
Prior art keywords
antibody
cell
peptide linker
binding moiety
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201911015236.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN110669137A (zh
Inventor
高新
钱尼良
李宏杰
杨翠马
王富玉
潘秀颉
刘蕴慧
胡冬梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Mianyifangzhou Medicine Technology Co ltd
Original Assignee
Beijing Mianyifangzhou Medicine Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Mianyifangzhou Medicine Technology Co ltd filed Critical Beijing Mianyifangzhou Medicine Technology Co ltd
Priority to CN201911015236.1A priority Critical patent/CN110669137B/zh
Priority to CN202110525473.3A priority patent/CN113416258B/zh
Publication of CN110669137A publication Critical patent/CN110669137A/zh
Priority to US17/292,739 priority patent/US12415852B2/en
Priority to EP20878020.5A priority patent/EP3868788A4/en
Priority to PCT/CN2020/100892 priority patent/WO2021077806A1/zh
Priority to AU2020371001A priority patent/AU2020371001A1/en
Priority to KR1020217015906A priority patent/KR20220087402A/ko
Priority to JP2021537127A priority patent/JP2022553464A/ja
Application granted granted Critical
Publication of CN110669137B publication Critical patent/CN110669137B/zh
Priority to JP2025088503A priority patent/JP2025143248A/ja
Priority to US19/305,277 priority patent/US20260001947A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201911015236.1A 2019-10-24 2019-10-24 一种多特异性抗体及其制备方法和用途 Active CN110669137B (zh)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN201911015236.1A CN110669137B (zh) 2019-10-24 2019-10-24 一种多特异性抗体及其制备方法和用途
CN202110525473.3A CN113416258B (zh) 2019-10-24 2019-10-24 一种多特异性抗体及其制备方法和用途
US17/292,739 US12415852B2 (en) 2019-10-24 2020-07-08 Multispecific antibody and preparation method and use thereof
EP20878020.5A EP3868788A4 (en) 2019-10-24 2020-07-08 MULTISPECIFIC ANTIBODY, METHODS FOR ITS PRODUCTION AND ITS USE
PCT/CN2020/100892 WO2021077806A1 (zh) 2019-10-24 2020-07-08 一种多特异性抗体及其制备方法和用途
AU2020371001A AU2020371001A1 (en) 2019-10-24 2020-07-08 Multi-specific antibody, preparation method therefor and application thereof
KR1020217015906A KR20220087402A (ko) 2019-10-24 2020-07-08 다중특이성 항체 및 그 제조 방법과 용도
JP2021537127A JP2022553464A (ja) 2019-10-24 2020-07-08 多重特異性抗体とその製造方法および使用
JP2025088503A JP2025143248A (ja) 2019-10-24 2025-05-28 多重特異性抗体とその製造方法および使用
US19/305,277 US20260001947A1 (en) 2019-10-24 2025-08-20 Multispecific antibody and preparation method and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911015236.1A CN110669137B (zh) 2019-10-24 2019-10-24 一种多特异性抗体及其制备方法和用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110525473.3A Division CN113416258B (zh) 2019-10-24 2019-10-24 一种多特异性抗体及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN110669137A CN110669137A (zh) 2020-01-10
CN110669137B true CN110669137B (zh) 2021-07-16

Family

ID=69083964

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201911015236.1A Active CN110669137B (zh) 2019-10-24 2019-10-24 一种多特异性抗体及其制备方法和用途
CN202110525473.3A Active CN113416258B (zh) 2019-10-24 2019-10-24 一种多特异性抗体及其制备方法和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110525473.3A Active CN113416258B (zh) 2019-10-24 2019-10-24 一种多特异性抗体及其制备方法和用途

Country Status (7)

Country Link
US (2) US12415852B2 (enExample)
EP (1) EP3868788A4 (enExample)
JP (2) JP2022553464A (enExample)
KR (1) KR20220087402A (enExample)
CN (2) CN110669137B (enExample)
AU (1) AU2020371001A1 (enExample)
WO (1) WO2021077806A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110669137B (zh) * 2019-10-24 2021-07-16 高新 一种多特异性抗体及其制备方法和用途
CN113214406B (zh) * 2020-01-21 2022-08-02 苏州普乐康医药科技有限公司 一种结合gpc3融合蛋白的制备方法及应用
CN112336873B (zh) 2020-08-04 2022-04-19 华南理工大学 用于多特异性抗体递送的蛋白型纳米颗粒及其应用、制备方法
CN114478788B (zh) * 2020-11-11 2025-07-18 北京免疫方舟医药科技有限公司 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途
KR102618718B1 (ko) * 2021-01-11 2023-12-29 주식회사 유틸렉스 항-4-1bb 항체 및 pd-1 단백질 또는 이의 단편을 포함하는 이중특이적 에피토프 결합 단백질 및 이의 용도
CN113527503A (zh) * 2021-07-27 2021-10-22 福建医科大学 一种用于类风湿性关节炎的抗VEGF和TNF-α双特异性纳米抗体融合蛋白
US20240417469A1 (en) * 2021-10-12 2024-12-19 Concept To Medicine Biotech Co., Ltd. Cd3-targeting t-cell engagers with improved therapeutic index
CN114409797B (zh) * 2021-12-24 2024-02-20 合肥天港免疫药物有限公司 重组抗体及其应用
CN116640224A (zh) * 2022-02-16 2023-08-25 北京免疫方舟医药科技有限公司 Cd137抗体和cd40l的融合蛋白及其应用
CN114380917B (zh) * 2022-03-25 2022-06-14 南京融捷康生物科技有限公司 针对IL-17A和TNFα的双特异性单域抗体及其用途
CN115368448B (zh) * 2022-07-19 2025-08-01 合肥天港免疫药物有限公司 双特异性抗体及其应用
US20260116960A1 (en) * 2022-09-29 2026-04-30 Shanghai Hongcheng Biopharmaceutical Co., Ltd. Trispecific antibodies targeting pd-1, ctla-4 and vegf and use thereof
CN115969997B (zh) * 2022-12-19 2024-02-13 华润生物医药有限公司 一种靶向cldn18.2的抗体药物偶联物及其应用
CN116987198B (zh) * 2023-09-28 2023-12-26 军科正源（北京）药物研究有限责任公司 一种靶向人pd-l1的融合蛋白及其用途
CN117843803B (zh) * 2023-12-29 2024-11-29 北京贝来药业有限公司 串联单域抗体及其在疾病治疗中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103781801A (zh) * 2011-08-23 2014-05-07 罗切格利卡特公司 包含两个Fab片段的无Fc的抗体及使用方法
WO2015197772A1 (en) * 2014-06-25 2015-12-30 Ucb Biopharma Sprl Multispecific antibody constructs
CN106459220A (zh) * 2014-05-29 2017-02-22 Ucb生物制药私人有限公司 适用于高通量筛选的新的双特异性形式
CN107406497A (zh) * 2014-12-19 2017-11-28 埃博灵克斯股份有限公司 半胱氨酸连接的纳米抗体二聚体
CN108473556A (zh) * 2015-12-03 2018-08-31 Ucb生物制药私人有限公司 多特异性抗体

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) * 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
WO1992022324A1 (en) * 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
CN100497390C (zh) * 2003-06-27 2009-06-10 比奥根艾迪克Ma公司 疏水-相互作用-层析或铰链区修饰对于均质抗体溶液的制备的用途
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
RU2531754C2 (ru) * 2008-04-11 2014-10-27 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
JP5522405B2 (ja) 2008-04-25 2014-06-18 協和発酵キリン株式会社 安定な多価抗体
EP2285833B1 (en) * 2008-05-16 2014-12-17 Ablynx N.V. AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
TW201138821A (en) * 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
EP2748202B1 (en) 2011-08-23 2018-07-04 Roche Glycart AG Bispecific antigen binding molecules
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
WO2015103549A1 (en) * 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
AU2015237864B2 (en) * 2014-03-24 2020-12-03 Cancer Research Technology Limited Modified antibodies containing modified IgG2 domains which elicit agonist or antagonistic properties and use thereof
MX2016014434A (es) * 2014-05-13 2017-02-23 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
WO2016001810A1 (en) * 2014-07-01 2016-01-07 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
CN104592392B (zh) * 2015-01-21 2018-08-28 武汉友芝友生物制药有限公司 一种双特异性抗体EpCAM×CD3的构建及应用
EP3967755B1 (en) * 2014-12-19 2024-03-27 Inozyme Pharma, Inc. Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
JP6180663B2 (ja) * 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
CN104558191B (zh) * 2015-01-21 2020-08-21 武汉友芝友生物制药有限公司 一种双特异性抗体cd20×cd3的构建及应用
GB201522391D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
SG11201809316XA (en) * 2016-04-28 2018-11-29 Biomunex Pharmaceuticals Bispecific antibodies targeting egfr and her2
EP3544628A4 (en) 2016-11-23 2020-11-18 Immunoah Therapeutics, Inc. 4-1BB BINDING PROTEINS AND THEIR USES
AU2018228435C1 (en) * 2017-03-02 2025-09-18 National Research Council Of Canada TGF-beta-receptor ectodomain fusion molecules and uses thereof
CN107266567B (zh) * 2017-06-05 2021-06-04 高新 Lcrmp4单克隆抗体及其制备方法与应用
JP7500619B2 (ja) * 2019-05-30 2024-06-17 アムジエン・インコーポレーテツド 抗体の二量体化を促進するためのヒンジ領域の操作
CN110669137B (zh) * 2019-10-24 2021-07-16 高新 一种多特异性抗体及其制备方法和用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103781801A (zh) * 2011-08-23 2014-05-07 罗切格利卡特公司 包含两个Fab片段的无Fc的抗体及使用方法
CN106459220A (zh) * 2014-05-29 2017-02-22 Ucb生物制药私人有限公司 适用于高通量筛选的新的双特异性形式
WO2015197772A1 (en) * 2014-06-25 2015-12-30 Ucb Biopharma Sprl Multispecific antibody constructs
CN107406497A (zh) * 2014-12-19 2017-11-28 埃博灵克斯股份有限公司 半胱氨酸连接的纳米抗体二聚体
CN108473556A (zh) * 2015-12-03 2018-08-31 Ucb生物制药私人有限公司 多特异性抗体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion;Johnson,S等;《JOURNAL OF MOLECULAR BIOLOGY》;20100409;第399卷(第3期);第437页左栏第3段至右栏第2段,第438页左栏第1段至右栏第2段,第439页左栏第1段、右栏第2-3段及图1 *
Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives;Schoonjans,R等;《JOURNAL OF IMMUNOLOGY》;20000926;第165卷(第12期);第7050页摘要,第7051页左栏第2段-右栏第6段,第7052-7055页结果部分,第7055页左栏第1段,第7056页左栏第2段-右栏第3段,图1 *
IgG H chain [Homo sapiens],GenBank: BAN63150.1;Sasaki,T等;《GenBank》;20130717;CDS和ORIGIN部分 *

Also Published As

Publication number Publication date
JP2025143248A (ja) 2025-10-01
CN110669137A (zh) 2020-01-10
US20210388077A1 (en) 2021-12-16
CN113416258B (zh) 2023-08-29
AU2020371001A1 (en) 2021-06-10
CN113416258A (zh) 2021-09-21
EP3868788A1 (en) 2021-08-25
KR20220087402A (ko) 2022-06-24
US12415852B2 (en) 2025-09-16
EP3868788A4 (en) 2022-08-24
US20260001947A1 (en) 2026-01-01
WO2021077806A1 (zh) 2021-04-29
JP2022553464A (ja) 2022-12-23

Similar Documents

Publication Publication Date Title
CN110669137B (zh) 一种多特异性抗体及其制备方法和用途
JP7062025B2 (ja) 修飾ｊ鎖
TWI815306B (zh) PD-1/TGF-beta四價雙特異性抗體、其製備方法和用途
CN114127111A (zh) 与nkp30结合的抗体分子及其用途
US20230090014A1 (en) Anti-cd47/anti-pd-l1 antibody and applications thereof
JP2018522564A (ja) 抗グリピカン３抗体およびその使用
IL304898A (en) New anti-CD24 antibodies
JP2023539645A (ja) Ｎｋｐ３０に結合する抗体分子およびその使用
JP2024531900A (ja) 新規の抗ｓｉｒｐａ抗体
CN118251419A (zh) 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途
US20250381223A1 (en) Humanized anti-cd28 antibody and bispecific antibody thereof with anti-cd40 antibody
CN114478788B (zh) 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途
CN116891530A (zh) 双特异性抗体及其应用
WO2022100694A1 (zh) 抗体及其制备方法
WO2025026282A1 (en) Modified type e multi-specific antibodies
WO2024027120A1 (en) Multi-specific polypeptide complexes
HK40126767A (zh) 抗cd3抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20200714

Address after: M2, building 9, Shouhui Plaza, 78 West Fourth Ring Road, Fengtai District, Beijing 100039

Applicant after: Gao Xin

Address before: 100039 201, 2 / F, 1-3 / F, building 9, yard 78, West Fourth Ring Middle Road, Fengtai District, Beijing

Applicant before: BEIJING MIANYIFANGZHOU MEDICINE TECHNOLOGY Co.,Ltd.

TA01 Transfer of patent application right
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20200110

Assignee: Guangxi Lugang Biomedical Technology Co.,Ltd.

Assignor: Gao Xin

Contract record no.: X2021110000015

Denomination of invention: A multi specific antibody and its preparation method and Application

License type: Common License

Record date: 20210325

EE01 Entry into force of recordation of patent licensing contract
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20211221

Address after: 100160 No. 847, 101, floor 9, building 19, zone 16 (Fenghai Lianchuang maker space), No. 188, South Fourth Ring West Road, Fengtai District, Beijing

Patentee after: BEIJING MIANYIFANGZHOU MEDICINE TECHNOLOGY Co.,Ltd.

Address before: 100039 m2, building 9, Shouhui Plaza, 78 West Fourth Ring Middle Road, Fengtai District, Beijing

Patentee before: Gao Xin

TR01 Transfer of patent right